Management of disease- and therapy-related adverse events

Dragana M. Jovanovic (Beograd, Republic of Serbia)

Source: ERS Online Course 2019: Essentials of modern lung cancer care – catch up with the latest advances
Number: 7
Disease area: -

PDF journal article, handout or slidesSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Dragana M. Jovanovic (Beograd, Republic of Serbia). Management of disease- and therapy-related adverse events. ERS Online Course 2019: Essentials of modern lung cancer care – catch up with the latest advances

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Predictors of immunotherapy induced immune-related adverse events
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Adverse anti-tuberculosis drug events and their management
Source: Eur Respir Monogr 2018; 82: 205-227
Year: 2018


Monitoring asthma in children: treatment-related issues
Source: International Congress 2014 – Monitoring asthma in children: results of the ERS Task Force
Year: 2014



Exercise: management of adverse events: discussion of clinical cases
Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination
Year: 2012


Severe adverse effects of antitubercular drugs and patient management
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011


Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019

Asthma exacerbations during pregnancy increase risk of adverse perinatal outcomes
Source: Virtual Congress 2020 – Diagnosis and management of asthma
Year: 2020




Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations)
Source: Eur Respir J 2007; 30: Suppl. 51, 125s
Year: 2007

Late Breaking Abstract - Cardiovascular adverse events of drugs targeting IL-5 in severe asthma: a pharmacovigilance study
Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights
Year: 2020




Risk factors for impaired pulmonary function in adult survivors of childhood hematological and non-hematological malignancies
Source: Virtual Congress 2020 – Management of chronic lung conditions
Year: 2020

Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008


Risk of serious adverse reactions during the treatment of new tuberculosis patients
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012

Adverse events and cardiovasular effects of vilanterol in paediatric asthma: a systematic review
Source: International Congress 2019 – Severe acute asthma and troublesome wheezing
Year: 2019

Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012


LATE-BREAKING ABSTRACT: Predictors of adverse outcome in severe pneumonia
Source: Annual Congress 2013 –Research questions on how viruses affect the respiratory system
Year: 2013


Predictable adverse events such as respiratory depression highlight the need for caution when prescribing morphine for refractory breathlessness
Source: Eur Respir J, 50 (3) 1701357; 10.1183/13993003.01357-2017
Year: 2017



Possible neuropsychic adverse reactions with montelukast in childhood asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 263s
Year: 2001

Pregnancy complications and respiratory problems in childhood
Source: International Congress 2015 – Risk factors and early origins of respiratory diseases
Year: 2015

The influencing of respiratory adverse effects of enalapril
Source: Eur Respir J 2001; 18: Suppl. 33, 264s
Year: 2001

Accuracy in assessment of acute asthma needs improved to avoid potential adverse outcomes
Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments
Year: 2012